Leadership & Pay ·
Nexalin Technology part ways with SVP Carolyn Shelton under separation agreement including $20,000 bonus and accelerated stock option vesting
NXLNexalin Technology, Inc.
On August 28, 2026, Carolyn Shelton departed her role as Senior Vice President of Quality, Regulatory, and Clinical Affairs at Nexalin Technology, Inc. The separation agreement provides for one month of continued base salary, a $20,000 bonus for 2026, accelerated vesting of unvested stock options, up to two years to exercise vested options, and health insurance premium subsidies through September 30, 2026. Ms. Shelton agreed to release claims against the company in exchange for these terms. Nexalin Technology operates in the medical device industry, developing neuromodulation therapies.